Annual EBITDA:
-$241.49M-$64.63M(-36.54%)Summary
- As of today, NAMS annual EBITDA is -$241.49 million, with the most recent change of -$64.63 million (-36.54%) on December 31, 2024.
- During the last 3 years, NAMS annual EBITDA has fallen by -$200.12 million (-483.74%).
- NAMS annual EBITDA is now -3533.17% below its all-time high of -$6.65 million, reached on December 1, 2020.
Performance
NAMS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$55.08M-$19.49M(-54.76%)Summary
- As of today, NAMS quarterly EBITDA is -$55.08 million, with the most recent change of -$19.49 million (-54.76%) on September 30, 2025.
- Over the past year, NAMS quarterly EBITDA has dropped by -$30.74 million (-126.33%).
- NAMS quarterly EBITDA is now -43031.56% below its all-time high of -$127.70 thousand, reached on December 1, 2020.
Performance
NAMS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$202.72M-$30.74M(-17.88%)Summary
- As of today, NAMS TTM EBITDA is -$202.72 million, with the most recent change of -$30.74 million (-17.88%) on September 30, 2025.
- Over the past year, NAMS TTM EBITDA has dropped by -$71.25 million (-54.20%).
- NAMS TTM EBITDA is now -158647.06% below its all-time high of -$127.70 thousand, reached on December 1, 2020.
Performance
NAMS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
NAMS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -36.5% | -126.3% | -54.2% |
| 3Y3 Years | -483.7% | -2301.4% | -3887.7% |
| 5Y5 Years | -3533.2% | -10000.0% | -10000.0% |
NAMS EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -981.0% | at low | -2301.4% | +20.0% | -3887.7% | at low |
| 5Y | 5-Year | -3533.2% | at low | >-9999.0% | +20.0% | >-9999.0% | at low |
| All-Time | All-Time | -3533.2% | at low | >-9999.0% | +20.0% | >-9999.0% | at low |
NAMS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$55.08M(-54.8%) | -$202.72M(-17.9%) |
| Jun 2025 | - | -$35.59M(+48.3%) | -$171.98M(+8.8%) |
| Mar 2025 | - | -$68.87M(-59.5%) | -$188.58M(-8.0%) |
| Dec 2024 | -$241.49M(-36.5%) | -$43.18M(-77.4%) | -$174.65M(-32.8%) |
| Sep 2024 | - | -$24.34M(+53.4%) | -$131.47M(-22.7%) |
| Jun 2024 | - | -$52.20M(+5.0%) | -$107.13M(-95.0%) |
| Mar 2024 | - | -$54.94M(-54.7%) | -$54.94M(-38.0%) |
| Dec 2023 | -$176.86M(-691.7%) | - | - |
| Mar 2023 | - | -$35.51M | -$39.80M |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$22.34M(+46.0%) | - | - |
| Sep 2022 | - | -$2.29M(-15.2%) | -$5.08M(-60.9%) |
| Jun 2022 | - | -$1.99M(-477.7%) | -$3.16M(-114.4%) |
| Mar 2022 | - | -$344.60K(+24.2%) | -$1.47M(-7.9%) |
| Dec 2021 | -$41.37M(-522.4%) | -$454.60K(-23.1%) | -$1.37M(-31.5%) |
| Sep 2021 | - | -$369.20K(-21.0%) | -$1.04M(-55.1%) |
| Jun 2021 | - | -$305.20K(-28.7%) | -$670.10K(-83.6%) |
| Mar 2021 | - | -$237.20K(-85.7%) | -$364.90K(-185.7%) |
| Dec 2020 | -$6.65M | -$127.70K | -$127.70K |
FAQ
- What is NewAmsterdam Pharma Company N.V. annual EBITDA?
- What is the all-time high annual EBITDA for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. annual EBITDA year-on-year change?
- What is NewAmsterdam Pharma Company N.V. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. quarterly EBITDA year-on-year change?
- What is NewAmsterdam Pharma Company N.V. TTM EBITDA?
- What is the all-time high TTM EBITDA for NewAmsterdam Pharma Company N.V.?
- What is NewAmsterdam Pharma Company N.V. TTM EBITDA year-on-year change?
What is NewAmsterdam Pharma Company N.V. annual EBITDA?
The current annual EBITDA of NAMS is -$241.49M
What is the all-time high annual EBITDA for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high annual EBITDA is -$6.65M
What is NewAmsterdam Pharma Company N.V. annual EBITDA year-on-year change?
Over the past year, NAMS annual EBITDA has changed by -$64.63M (-36.54%)
What is NewAmsterdam Pharma Company N.V. quarterly EBITDA?
The current quarterly EBITDA of NAMS is -$55.08M
What is the all-time high quarterly EBITDA for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high quarterly EBITDA is -$127.70K
What is NewAmsterdam Pharma Company N.V. quarterly EBITDA year-on-year change?
Over the past year, NAMS quarterly EBITDA has changed by -$30.74M (-126.33%)
What is NewAmsterdam Pharma Company N.V. TTM EBITDA?
The current TTM EBITDA of NAMS is -$202.72M
What is the all-time high TTM EBITDA for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. all-time high TTM EBITDA is -$127.70K
What is NewAmsterdam Pharma Company N.V. TTM EBITDA year-on-year change?
Over the past year, NAMS TTM EBITDA has changed by -$71.25M (-54.20%)